US: Pharmaceuticals
featured
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
» Read More
More
-
*Q4 sales $7.28 billion vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss warned on Thursday the drugmaker faced a tough year in 2013, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continue to erode business.
-
NEW YORK-- Shares of Isis Pharmaceuticals Inc. soared Wednesday on news that the U.S. Food and Drug Administration approved its new drug application for its Kynamro cholesterol drug. Carlsbad, Calif.- based Isis has a deal with Genzyme, a unit of French drugmaker Sanofi SA, to market the drug if it is approved.
-
Jan 30- AbbVie, the pharmaceuticals business spun off earlier this month by Abbott Laboratories, forecast 2013 earnings in line with Wall Street forecasts but slowing sales growth for its blockbuster Humira rheumatoid arthritis drug. AbbVie said it expects net earnings this year of $2.66 to $2.76 per share.
-
Jan 30- AbbVie, the pharmaceuticals business spun off earlier this month by Abbott Laboratories, forecast 2013 earnings in line with Wall Street forecasts. AbbVie said it expects net earnings this year of $2.66 to $2.76 per share. Abbott last week said global sales of branded drugs that now belong to AbbVie rose 7.4 percent to $5.14 billion.
-
*To pay 7.35 Sfr per share dividend for 2012. BASEL, Jan 30- Swiss drugmaker Roche forecast a rise in sales and profits this year, helped by new cancer medicines it hopes will shield it from the patent expiries ravaging many rivals.
-
Peer Schatz, CEO of Qiagen, tells CNBC they are looking at increasing the outlook for 2013 but will continue to manage the bottom line very actively.
-
Severin Schwan, CEO of Roche, tells CNBC that 2012 was a very good year for Roche with the company outgrowing their markets in both Pharma and Diagnostics by five and four percent.
-
Emerging markets, and in particular, Latin America will be the drivers for continued growth, Swiss drug maker Roche told CNBC, even as the company faces price pressures elsewhere.
-
CAMBRIDGE, Mass.-- Specialty drugmaker Vertex Pharmaceuticals Inc. swung to a loss in the fourth quarter as doctors turned away from the company's best-selling drug for treating hepatitis C. Most of the decline was due to lower sales of the company's hepatitis C pill, Incivek, which contributed $223 million, down from $457 million.
-
During a conference call with analysts on Pfizer Inc.' s fourth-quarter results, executives of the drugmaker were asked about plans to acquire new businesses, even as the drug giant has been streamlining to cut costs and divest noncore businesses. Chief Financial Officer Frank D'Amelio outlined what the drugmaker might be looking for.
-
Jan 29- Pfizer Inc and Eli Lilly and Co reported better-than-expected fourth-quarter profits as deals, cost cutting and strong sales of new products helped the pharmaceutical companies weather generic competition for once top-selling products.
-
*R&D tax credit to add 7 cents to 2013 EPS. The U.S. drugmaker earned $827 million, or 74 cents per share, down from $858 million, or 77 cents per share, a year earlier. Excluding special items such as asset impairments and restructuring, Lilly earned 85 cents per share, beating analysts' expectations by 7 cents per share.
-
Jan 29- Pfizer Inc on Tuesday reported better-than-expected fourth-quarter results, helped by rebounding sales in emerging markets, but the drugmaker forecast earnings for 2013 that was mostly below consensus analyst expectations.
-
Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter profit fell as competition from generic drugs, particularly for its once top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, down from $858 million, or 77 cents per share, a year earlier.
-
Eli Lilly said fourth-quarter earnings fell as competition from generic drugs, particularly for Zyprexa, drove revenue lower.
-
Jan 29- Pfizer Inc on Tuesday reported better-than-expected quarterly results, helped by a rebound in sales in emerging markets. The largest U.S. drugmaker said it earned $6.32 billion, or 86 cents per share, in the fourth quarter. That compared with $1.44 billion, or 19 cents per share, in the year-earlier quarter.
-
Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings fell as competition from generic drugs, particularly for its top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.
-
Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings had fallen as competition from generic drugs drove revenue lower. The U.S. drugmaker said it had earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.
-
Barbara Ryan, former Deutsche Bank senior pharma analyst, tells CNBC why investing in innovation is critical if pharmaceutical companies are to continue to make money.
-
Jan 29- Pfizer Inc and Eli Lilly and Co both reported a better-than-expected fourth-quarter profit as they weathered generic competition for once top-selling products through deals, cost cutting and strong sales of newer products.